The global perfusion systems market was valued at USD 1.15 billion in 2023 and is projected to reach USD 1.94 billion by 2034, growing at a CAGR of 4.85% during the forecast period (2024–2034). This growth is fueled by rising organ transplantation needs, technological innovations, and increasing investments in biopharma R&D.
Download the free sample for a quick preview, or get the full report for complete insights and forecasts on the In Vitro Diagnostics Market @ https://www.towardshealthcare.com/download-sample/5234
North America dominated the global market with a 40% share in 2023, led by high transplant volumes and advanced healthcare infrastructure.
Asia-Pacific is expected to grow significantly due to its large aging population and rising organ transplant demand.
Cardiopulmonary perfusion systems held the largest share in 2023, driven by rising cardiovascular surgeries.
Cell perfusion systems are projected to grow rapidly due to increasing application in drug testing, biomanufacturing, and stem cell therapies.
Rising Organ Transplantation
Over 48,000 organ transplants were performed in 2024 (Organ Procurement and Transplantation Network).
North America leads globally in organ donation and transplants, especially the US.
Integration of AI in Perfusion
AI and machine learning improve organ assessment, transplant predictions, and bioprocess automation.
Helps reduce organ discard rates and increases success in organ preservation and matching.
Biopharmaceutical R&D Boost
NIH invested $48 billion annually, and top 20 pharma companies invested $145 billion in 2022-23 in R&D.
Growing focus on continuous biomanufacturing and cell-based therapies fuels perfusion system demand.
Technological Advancements
Launch of next-gen systems like LivaNova’s Essenz Perfusion System and Paragonix’s KidneyVault are transforming the landscape.
Innovations in single-use bioreactors, microfluidic systems, and portable hypothermic perfusion devices increase accessibility and efficiency.
Increasing chronic illnesses like cardiovascular, respiratory, renal, and liver diseases.
Need for effective organ preservation solutions before transplantation.
Technological shift from cold static storage to machine perfusion.
High cost of perfusion systems: ~$456,455 in the US; ₹11,000–18,00,000 in India.
Lack of skilled professionals for complex systems.
Challenges in scalability and adoption, especially in low-income countries.
Expanding use in biopharma for continuous culture and high-yield production.
New applications in stem cell therapy, 3D cell culture, and toxicology testing.
Government initiatives and increasing awareness around organ donation.
Accounted for 40% of the global market in 2023.
Over 46,000 organ transplants in the US alone.
Backed by advanced healthcare systems, R&D funding, and favorable regulations.
Key players: TransMedics, LivaNova, Medtronic.
High growth due to aging population, chronic disease burden, and government policies promoting organ donation.
India and China rank among top three countries in organ transplants.
Rising healthcare infrastructure and investment in biopharma manufacturing.
Strong R&D, early technology adoption, and supportive healthcare policies.
Countries like Spain lead globally in donation activity with 48.9 donors per million.
LivaNova, headquartered in the UK, is a major player with regional expansion.
Used during heart and lung surgeries.
Includes heart-lung machines, oxygenators, cannulas, and monitoring devices.
Increasing cases of open-heart surgery (2M+ annually worldwide).
Supports high-density cell culture for longer durations.
Essential for biomanufacturing, drug screening, stem cell research.
Includes bioreactor, microfluidic, and gravity-driven systems.
VersaLive platform by TIGEM (Italy) is a notable innovation for live cell imaging and transfection.
Classified into hypothermic and normothermic techniques.
Used to preserve organs like liver, heart, lungs, and kidneys outside the body.
AutoMate Scientific
Bridge to Life, Ltd.
Cytiva
Harvard Apparatus
Hugo Sachs Elecktronik
LivaNova PLC
MedicalExpo
Medtronic
Nipro Corporation
Paragonix Technologies
Repligen
Sartorius
Thermo Fisher Scientific
TransMedics Group, Inc.
What is a perfusion system?
A perfusion system is a tool used to circulate a nutrient medium through organs or cells to keep them viable for research, transplantation, or biomanufacturing.
Which segment is dominating the perfusion systems market?
The Cardiopulmonary Perfusion System segment is currently dominating due to high volumes of heart and lung surgeries worldwide.
What is driving the growth of cell perfusion systems?
The demand for continuous and scalable biomanufacturing in the pharmaceutical industry and advancements in stem cell research are key drivers.
How is AI being used in perfusion systems?
AI helps predict transplant outcomes, automate perfusion processes, and analyze clinical data for organ viability—thereby improving patient outcomes.
Which region has the highest growth potential?
Asia-Pacific is expected to grow the fastest due to a rising geriatric population, chronic illnesses, and increasing organ donations.
Check out below
Immediate Delivery Available | Buy This Premium Research @ https://www.towardshealthcare.com/price/5234
Access our exclusive, data-rich dashboard dedicated to the diagnostics sector – built specifically for decision-makers, strategists, and industry leaders. The dashboard features comprehensive statistical data, segment-wise market breakdowns, regional performance shares, detailed company profiles, annual updates, and much more. From market sizing to competitive intelligence, this powerful tool is one-stop solution to your gateway.
Access the Dashboard: https://www.towardshealthcare.com/access-dashboard
Become a valued research partner with us – https://www.towardshealthcare.com/schedule-meeting
You can place an order or ask any questions, please feel free to contact us at sales@towardshealthcare.com
The global in vitro diagnostics market is witnessing strong growth, with a projected market size of USD 123.45 billion by 2034,… Read More
Chinese biopharmaceutical innovator Mabwell has announced a major milestone in its oncology pipeline: its proprietary CDH17-targeting antibody-drug conjugate (ADC), 7MW4911,… Read More
Global medical technology leader Demetra has announced the launch of its new spine-focused division, Demetra Spine, following its strategic acquisition… Read More
A groundbreaking multi-institutional study has uncovered a hidden mechanism potentially responsible for the high recurrence rate in ovarian cancer patients,… Read More
In a promising turn for brain cancer research, funding for glioblastoma (GBM) has seen a significant uptick, spurred by nonprofit… Read More
Seoul, South Korea Lotte Biologics is making significant strides in expanding its global presence in the Contract Development and Manufacturing… Read More